a historic day for sarepta. skyrocketing more than 70% on the fda decision to fast track approval for a drug used to trade mus call oar dystrophy. they are at the highest level since 2002. meg tirrell joins us with ed kaye as interim ceo. meg, take it away. >> dr. kaye, thank you for being here. a historic day for sarepta. what is next for getting the drug out on the market and to patients. >> well, we're very excited. and i think we're very excited for the patients. they've been waiting for a drug like this for a very long time. so our focus is going to be to make sure that we get the drug out and to the community and into the boys as soon as possible. we're ready to launch. we have sales force. we have distribution centers ready to go. we have reimbursement people that are active and in cambridge and ready to work. so that will be the first focus and making sure everybody who wants the drug can get it. the next thing we're doing is making sure that we're working on our other products that can address many more

. >> sarepta. i gave you all of my reasons before. buy the stock. >> b.k. >> watch natural gas and buy apache. >> everything should be sold. >> "mad money" starts right now. >>> my mission is simple, to make you money. i'm here to level the playing field for all investors. there's always a bull market somewhere, and i promise to help you find it. "mad money" starts now! >>> hey, i'm cramer. welcome to "mad money." welcome to cramerica. other people want to make friends. i'm just trying to make you some money. my job is not just to entertain you, but to educate and teach you. so call me at 1-800-743-cnbc or tweet me @jimcramer. how do you remove the fed and oil from the story of this market? how do we get the focus back on individual companies? not the overall obsession with what the fed will do on wednesday or what direction oil might be heading on a minute to minute basis. both of these factors were in play again today as usual. in a deceptively quiet market with the dow ultimately just setting off four points, s&p closing essentiall

after sarepta's over 70% move higher today. feel like it's time to go hunting for the next speculative biotech? don't make a move before you hear what i have to say. then did you notice the roller coaster action on the averages today? it all comes back to oil. i'll tell you why crude's in control. and all your calls rapid fire in tonight's edition of the lightning round. anyoit your numbers go up, despite your best efforts. but what if you could turn things around? what if you could... love your numbers? discover once-daily invokana?. it's the #1 prescribed sglt2 inhibitor that works to lower a1c. a pill taken just once in the morning, invokana? is used along with diet and exercise to significantly lower blood sugar to be more effective at lowering a1c than januvia. invokana? works around the clock by reducing the amount of sugar allowed back into the body, and sending some sugar out through the process of urination. and while it's not for lowering systolic blood pressure or weight loss, it may help you with both. invokana? can

the ceo of sarepta joins us. latest on the investigation into the terror attacks and hear from mayor kahn. later we will hear from a wells fargo activist investor who says john stumpf needs to resign. keep it right here. you are watching cnbc, first in business world wide. campus connected. and why a pro football team chose us to deliver fiber-enabled broadband to more than 65,000 fans. and why a leading car brand counts on us to keep their dealer network streamlined and nimble. businesses count on communication, and communication counts on centurylink. >>> welcome back. the suspect in the new york and new jersey bombings is in custody after shootout with police. >> the suspect has been apprehended. he was taken into custody after engaging in a shootout with police. he was shot several times but was conscious at the time of arrest. the investigation continues despite law enforcement officials saying there are no individuals that they -- no other individuals that they are looking for at this time. here on 23rd str

steve was fortunate enough to be in sarepta and caught the wave.ow do you know in an area risk and reward so outsized versus other parts of the market what's good and not good. >> i am fortunate enough to be with someone that knows what option strategies to take advantage. i don't like vaccines so i don't like them. it's worth to it pay it big and hit it eats way. i'm agnostic. there are ways to take advantage of it. you in many ways have brought them public to people and i salute you. it's too dicey to do comments what i'm saying. >> i agree, judge. you can define your risk but with an option why steven was trading them into this event as well. instead of $30 on the table and saying it's a binary bet, it could be $5 or 60. >> right. that's why steve snugged up a put against the stock he owned and got to ride it to the upside 20 bucks. >> i'm invested with a hedge fund manager who put up 30% returns a year for 16 years with one down year in '08, down less than the market, who knows what he's doing. to me, the individual investor should not invest i

my question is on sarepta therapeutics. >> all right. sarepta is a tough situation because there were articles yesterday about a guy from the fda who blocked and left. but then there were pieces of research today from the guy saying people in the fda are still against it. i think this thing all the way up at 30 is a little bit too dicey, too binary. how about ron in nevada. ron. >> caller: how are you doing, jim? >> i'm doing well, ron. how are you? >> caller: i'm good. i've got a stock, ren. >> oh, my god, resolute energy. this thing has gone from $100 million to like $260 million in zero to 60. but i think you missed a lot of rent frankly. i think you've missed too much rent as a matter of fact. how about carl in alaska? carl. booyah from the great state of alaska. >> done, yes. absolutely. >> caller: jim, i'd like to know what's your feelings on semiconductors on? >> yeah, they're making a merger. i think it's good. i do want to just mention -- i've been mentioning nxpi is my favorite. my charitable trust owns it. and how about the sk

hear what the ceo of sarepta has to say. we'll see you later. >> thanks. >> next up, o'leary on apple's jump. is he getting back in? the stock is down slightly today. it has a great run over the last week. we'll talk about that next. hey gary, what are you doing? oh hey john, i'm connecting our brains so we can share our amazing trading knowledge. that's a great idea, but why don't you just go to thinkorswim's chat rooms where you can share strategies, ideas, even actual trades with market professionals and thousands of other traders? i know. your brain told my brain before you told my face. mmm, blueberry? tap into the knowledge of other traders on thinkorswim. only at td ameritrade. that's why a cutting edgeworld. university counts on centurylink to keep their global campus connected. and why a pro football team chose us to deliver fiber-enabled broadband to more than 65,000 fans. and why a leading car brand counts on us to keep their dealer network streamlined and nimble. businesses count on communication, and communicati

. >>> up next, a big victory for one biotech investor who nailed his call on sarepta.t stock is up 89%. look at all 11, yes, 11 sectors on the s&p 500. reits today trading on their own as a group. "power lunch" is back in two. when a moment turns romantic, why pause to take a pill? or stop to find a bathroom? cialis for daily use is approved to treat both erectile dysfunction and the urinary symptoms of bph, like needing to go frequently, day or night. tell your doctor about all your medical conditions and medicines, and ask if your heart is healthy enough for sex. do not take cialis if you take nitrates for chest pain, or adempas for pulmonary hypertension, as it may cause an unsafe drop in blood pressure. do not drink alcohol in excess. side effects may include headache, upset stomach, delayed backache or muscle ache. to avoid long-term injury, get medical help right away for an erection lasting more than four hours. if you have any sudden decrease or loss in hearing or vision, or any symptoms of an allergic reaction, stop taking cialis and get medical help right awa

sarepta therapeutics jumping more than 10%.he fda will make a decision soon on whether to approve the company's treatment for genetic muscular disorder. >>> samsung says it will perform a software update to limit the charge on the galaxy note's 7 battery at 60%. the update is only available in south korea for now. the company also running local ads apologizing for the global recall of the phone following reports that the battery could cash fire while charging. i wonder if that will have an impact on the early numbers out of apple's iphone 7 sales yesterday. >>> hermes is suffering its worst day in six years. they are scrapping sales growth targets due to an increasingly uncertain sales target. stores still have not recovered following the paris attacks in nice in june. it's down 6.8%. luxury retail across the board in europe is suffering today. the likes of richemont and swatch as well. >> bill ackman has been a largest shareholder in the industrial gas and chemical company and led a push to cut costs. >>> jetblue says cfo mark

sarepta therapeutics. a drug has left the fda.ar, an fda panel voted against approving the drug, so it seemed like the drug may have a better chance of approval. ford shares are down. the company expects overall financial performance to decline next year as it rolls out a new growth plan. and it is an ugly day for first solar. that stock one of the worst performers in the s&p 500 and touching new lows not seen since april of 2013. >> oil plunging in the past hour. price closing, let's show you now, off by more than 3%. jackie deangelis at the nymex. >> it is interesting that earlier this morning when the inventory report came out from the doe, we saw a spike in oil prices turning positive. once people dug into the report and digested it a little bit more, they saw more than just a half a million barrel drawdown. they saw u.s. production was rising and imports were up as well. with that told, last week's number was a one off experience because of the weather. add to that, the gasoline actually added this week, and distylets were up

. >> carl, it's one of the most anticipated events of the year, sarepta getting approval for musculartock up 70% today on this surprise decision. most analysts expected this drug would be rejected because the number of patients that was tested was so small. this was a months long battle. decision from the fda was delayed by months. people didn't know which way this was going to go. but this drug getting approved by the fda sending sarepta up more than 70% today, guys. >> wow, that's a big move. meg, thank you. we'll continue to follow that. talking about the broader market here, biotech actually has had some interesting moves. there has been health care matters, i wonder if you think this is going to continue to be a hot area despite some of the political concerns, tom? >> i mean, i think health care is one of the true really good businesses in america, right? all the best health companies are in america and it is a good business. but as far as stocks, i think you should be a little more cautious on them because they had such leadership for the last seven years. and it's rare for stoc

jim, about three weeks ago, sarepta therapeutic came up with a price of $20. >> right. >> caller: itent up to $63. >> right. you know, we have now missed that stock, sir. i mean it is done -- it can still go higher, but i don't feel like we have any value added at this point. chuck in california. >> caller: i'm in golden state warrior country. dynasty, dynasty, dynasty. then i'd like to know about home depot. >> dynasty? home depot, yes. that's a good stock. over the year it's been flat lining and i think it's an opportunity. that, ladies and gentlemen, is the conclusion of the lightning round! >> announcer: the lightning round is sponsored by td ameritrade. >>> hey, i'm cramer. welcome to mad money. welcome to cramerica. >> this is a holiday special. remember. oh, trust me, the stock's rallied more than 18% year-to-date, not just because this is featured in every store near you. actually i've never seen it before other than on the set. [ blender whirring ] >> i like that. welcome to the selfie generation. we need to look good for impromptu posts from the subway, right, will? oh, gre

. >> sarepta, keeps giving. >> good stuff. thanks for watching. power starts now. >>> all right.hanks everybody. i'm brian sullivan. thanks for joining us. while on this first day of fall, stocks are on the rise. welcome to "power lunch." your money on the move again today, but there's always more opportunity somewhere. we're going to find it for you. forget piece of italy, why san francisco is the new unfortunate home to a very expensive leaning tower. and you think our politics are a little too punchy here in america? wait until you see what is happening in one european country. the must-see video coming your way as "power lunch" starts right now.

sarepta therapeutics and finally eli lilly has a phase three trial running in alzheimer's disease. >>one health care services entity under blue skyoffs late is centine. company is expanding under obama care while others have been pulling out of public exchanges. >> joining us is chairman, president and ceo of centine. what has been the impact of massive players like united health and others pulling out of the obama care exchanges? >> i think it has an impact on the overall industry and just highlights the need that after the election we need to fix it. there is a group of us that are doing just that. >> i'm curious what you see as a fix because it leaves a company like yours vulnerable to insuring the high cost people out there who are not -- you are not going to make money off of those guys. there will be more of those. >> we are operating below the minimum loss ratio. our costs can go up and won't change our bottom line. we are focussed on the medicaid what we call the people that move back and forth, the medicaid to aca. and that's different network. it's 92% subsidized. it's a goo

. >> sarepta, keeps giving. >> good stuff. thanks for watching. power starts now. >>> all right. thanks everybody. i'm brian sullivan. thanks for joining us. while on this first day of fall, stocks are on the rise. welcome to "power lunch." your money on the move again today, but there's always more opportunity somewhere. we're going to find it for you. forget piece of italy, why san francisco is the new unfortunate home to a very expensive leaning tower. and you think our politics are a little too punchy here in america? wait until you see what is happening in one european country. the must-see video coming your way as "power lunch" starts right now. >>> and welcome to "power lunch." i'm melissa lee. here's what else is happening at this hour. stocks pushing higher with the dow and the s&p 500 erasing all of september's losses while the nasdaq on pace for a record close here. existing home sales falling 0.9% last month. economists were looking for a gain. and north carolina under a state of emergency following days of chaotic street protests after the fatal shooting of a black m

if sarepta gets approval could go higher, if it doesn't, could go lower.his is a terrible disease. a lot of the people of the parents who had this went to the fda said the safety profile was fine, please give us something compassionately. i think this is a sign the fda is going to give them something. i think it's very good for the parents, of course for the sufferers. >> medical products and biotech, house oversight going to tackle epipen next week. >> saw that. >> there are some stories out this morning and yesterday about mylan's executive comp and how it compares to almost everyone except fregeneron. >> yeah. regeneron to create tremendous wealth, but more importantly remember you only have to have one injection in the eye per month versus every week with his mack lar degeneration drug. remarkable. i think when you get off the desk you hear mylan, hear teva, valeant, yesterday we had a story defense of valeant by bill miller. then again the stock is down gigantically. these are companies regarded as right on r & d and very aggressive on pricing. those